A recent study from Howard Hughes Medical Institute, Center for Stem Cell Biology, NYU School of Medicine, 550 First Avenue, New York, USA has reported the role of Notch-regulated lncRNA LUNARI in Acute Leukemia. This study was published in the July 31 2014 Cell (The number 1 journal in basic biology) by Prof Iannis Aifantis, Thomas Trimarchi and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Mechanistic and Therapeutic insights into the treatment of Human Leukemia: Tumor suppressor ARF inhibits acute leukemia via down regulation of Notch-regulated pro-oncogenic lncRNA LUNAR1. This study suggests that ARF, by decreasing the expression of Notch-1, lncRNA LUNAR1 and IGF1R mRNA, it may inhibit acute leukemia. Together, this study suggests that pharmacological formulations encompassing “ ARF activators” may be used to treat patients (with no mutation or deletion in the ARF gene) suffering from leukemia.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Mechanistic and Therapeutic insights into the treatment of Human Leukemia: Tumor suppressor ARF inhibits acute leukemia via down regulation of Notch-regulated pro-oncogenic lncRNA LUNAR1., 16/August/2014, 09.05 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
